Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.
Citi believes intismeran’s efficacy in melanoma is clinically meaningful, but patient selection, personalized manufacturing and efficacy across cancer types still limit its platform value; the kidney cancer trial will be the next major test.
Citi ·
Intismeran combined with Keytruda significantly improved recurrence-free survival after melanoma surgery, while early pancreatic cancer data provide mechanistic support for expansion into kidney cancer. But the wait for treatment to take effect, tissue sample requirements for manufacturing, and immature overall survival data still constrain the realization of the platform’s value.
Goldman Sachs ·
In the adjuvant pancreatic cancer data, 11 of 20 evaluable patients remained recurrence-free. JPMorgan believes the current efficacy evidence remains difficult to distinguish from chemotherapy alone, while Moderna’s valuation already incorporates expectations for broader indications and platform value.
J.P. Morgan ·
